-

Vetoquinol: 2025 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.

January 30, 2025

2024 Annual Sales (after market)

March 20, 2025

2024 Annual results (confcall after market)

April 24, 2025

2025 First quarter sales (after market)

May 22, 2025

Annual shareholders’ meeting

June 6, 2025

Dividend payment

September 11, 2025

2025 First semester results (confcall after market)

October 28, 2025

2025 Third quarter sales (after market)

Next update: Annual Sales 2024, January 30th, 2025 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

More News From Vetoquinol

Vetoquinol: Annual Results 2024

LURE, France--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "In 2024, we delivered a solid financial year, combining growth in almost all our reference markets, high profitability and sustained cash generation. We have achieved this performance while absorbing the sometimes significant uncertainties, such as in the United States this year, as well as the cost of transforming the Group. This is due to the strength of our model built a...

Vetoquinol: Annual Sales 2024

LURE, France--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "All our activities and territories are growing, with the exception of the United States for one-off reasons. We are on track to deliver long-term profitable growth. We owe this to our focus strategy and the power of our "Essentials" model, which has delivered average annual growth of over 8% for the past 10 years. We will continue to pursue this strategy in 2025." Vetoquino...

Vetoquinol: Sales at End September 2024

LURE, France--(BUSINESS WIRE)--Regulatory News: At the end of September 2024, Vetoquinol (Paris:VETO) sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates. Over the same period, the laboratory recorded net negative currency impacts of €-1 million, linked to the Americas and Asia Pacific/Rest of World territories, partially offset by positive currency impacts of +1.4M€ on the Europe territory. Sales of Essential products totaled €241 million, up +3.9% on...
Back to Newsroom